A newly approved, homegrown once-weekly GLP-1 receptor agonist is seeking to disrupt a diabetes space in China currently dominated by Novo Nordisk’s same-class global blockbuster Ozempic (semaglutide).
Shanghai Innogen Pharmaceuticals’ Diabegone (esubaglutide alfa, previously known as supaglutide) was approved on 26 January and is also set to take on two other heavyweights - Novo’s Rybelsus, a once-daily oral formulation of semaglutide and Eli Lilly’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?